Hepatitis vaccines

Infectious Disease Clinics of North America

Volumn 15, Issue 1, 2001, Pages 83-95

  Koff, Raymond S ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS VACCINE;

DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; INCIDENCE; INFECTION CONTROL; INFECTION RISK; REVIEW; VACCINATION; VIRUS HEPATITIS;

EID: 0035063445     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70269-5     Document Type: Article

References (46)

1. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX - In young adults
2. Prevalence of hepatitis C virus infection in patients hospitalized for hepatitis A
3. Who should receive hepatitis A vaccine?
4. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
5. Long-term followup of hepatitis A vaccination in children
6. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
7. Seroepidemiology of hepatitis B virus infection in children. Ten years of mass vaccination in Taiwan
8. Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants
9. Clinical experience with an inactivated hepatitis A vaccine
10. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens
11. Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A
12. Immunogenicity of hepatitis A vaccine in decompensated liver disease
13. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization
14. Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults
15. Naturally occurring variants of hepatitis B virus
16. A pilot study of CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
17. Hepatitis A vaccination of men who have sex with men - Atlanta, Georgia, 1996-1997
18. A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B
19. Protection against hepatitis A by an inactivated vaccine
20. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?
21. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
22. The case for routine childhood vaccination against hepatitis A
23. A two dose combined hepatitis A and B vaccine in Chinese youngsters
24. Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children
25. A two-dose hepatitis B vaccine regimen: Proof of priming and memory responses in young adults
26. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine
27. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994
28. Hepatitis A vaccination in chronic carriers of hepatitis B virus
29. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales
30. Hepatitis A virus infections in urban children - Are preventive opportunities being missed?
31. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant
32. Safety and immunogenicity of hepatitis A vaccine in infants: A candidate for inclusion in the childhood vaccination programme
33. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus
34. Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection
35. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: A randomised trial
36. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
37. The first combined vaccine against hepatitis A and B: An overview
38. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
39. Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults
40. Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant
41. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
42. Six years' follow-up after hepatitis A vaccination
43. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose
44. Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis B
45. Hepatitis B vaccination in high-risk infants: 10-year follow-up
46. Molecular epidemiology of hepatitis B virus mutants